FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023407910> ?p ?o ?g. }

• W2023407910 endingPage "55" @default.
• W2023407910 startingPage "48" @default.
• W2023407910 abstract "The combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4) is still a reference regimen in advanced colorectal cancer; however, the addition of new biologic compounds represents a significant way forward. Bortezomib is an inhibitor of proteasome, a multicatalytic enzyme complex that degrades several intracellular proteins. In this study, escalating doses of Bortezomib were administered along with the standard FOLFOX-4 doses, in order to evaluate the dose-limiting toxicity (DLT), toxicity profile and activity of the combination.Patients with advanced colorectal cancer, unpretreated for metastatic disease, were enroled in the study. Bortezomib starting dose was 1.3 mg/m2, which was to be escalated in the subsequent steps according to the toxicities observed after first cycle.Exploratory pharmacogenetics research was conducted by analysing the association between clinical outcomes and polymorphisms in candidate genes for response to each of the used drugs. Correlation between tumour marker changes and response was also investigated.One mg/m2 (DL-1) was defined as being the maximum tolerated dose since only 1 DLT was observed in 6 patients. The main toxicities were haematologic, neuropathy, diarrhoea and fatigue. Amongst 13 evaluable patients, five had a partial response, five had a stable disease and three patients progressed. Two patients are long-term survivors after a combined chemosurgical approach.Further trials of the current combination may be justified." @default.
• W2023407910 created "2016-06-24" @default.
• W2023407910 creator A5013792017 @default.
• W2023407910 creator A5046319428 @default.
• W2023407910 creator A5057207847 @default.
• W2023407910 creator A5061157288 @default.
• W2023407910 creator A5065493500 @default.
• W2023407910 creator A5079489429 @default.
• W2023407910 creator A5080693514 @default.
• W2023407910 creator A5087905831 @default.
• W2023407910 date "2009-01-01" @default.
• W2023407910 modified "2023-10-06" @default.
• W2023407910 title "An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer" @default.
• W2023407910 cites W1964175291 @default.
• W2023407910 cites W1970158990 @default.
• W2023407910 cites W1972978214 @default.
• W2023407910 cites W2013660816 @default.
• W2023407910 cites W2014637687 @default.
• W2023407910 cites W2025839879 @default.
• W2023407910 cites W2026043555 @default.
• W2023407910 cites W2032481064 @default.
• W2023407910 cites W2033764617 @default.
• W2023407910 cites W2065829703 @default.
• W2023407910 cites W2079100773 @default.
• W2023407910 cites W2080199075 @default.
• W2023407910 cites W2081381852 @default.
• W2023407910 cites W2092353844 @default.
• W2023407910 cites W2099878195 @default.
• W2023407910 cites W2107154392 @default.
• W2023407910 cites W2108235071 @default.
• W2023407910 cites W2110159294 @default.
• W2023407910 cites W2111810335 @default.
• W2023407910 cites W2121368761 @default.
• W2023407910 cites W2122684890 @default.
• W2023407910 cites W2123167232 @default.
• W2023407910 cites W2124560610 @default.
• W2023407910 cites W2126008131 @default.
• W2023407910 cites W2126750639 @default.
• W2023407910 cites W2136951601 @default.
• W2023407910 cites W2142564546 @default.
• W2023407910 cites W2150123812 @default.
• W2023407910 cites W2154533342 @default.
• W2023407910 cites W2155468968 @default.
• W2023407910 cites W2157769714 @default.
• W2023407910 cites W2164879306 @default.
• W2023407910 cites W2166350458 @default.
• W2023407910 cites W2166526813 @default.
• W2023407910 cites W2168082725 @default.
• W2023407910 cites W4293241248 @default.
• W2023407910 doi "https://doi.org/10.1016/j.ejca.2008.08.011" @default.
• W2023407910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18809314" @default.
• W2023407910 hasPublicationYear "2009" @default.
• W2023407910 type Work @default.
• W2023407910 sameAs 2023407910 @default.
• W2023407910 citedByCount "26" @default.
• W2023407910 countsByYear W20234079102012 @default.
• W2023407910 countsByYear W20234079102013 @default.
• W2023407910 countsByYear W20234079102014 @default.
• W2023407910 countsByYear W20234079102015 @default.
• W2023407910 countsByYear W20234079102017 @default.
• W2023407910 countsByYear W20234079102018 @default.
• W2023407910 countsByYear W20234079102021 @default.
• W2023407910 countsByYear W20234079102022 @default.
• W2023407910 countsByYear W20234079102023 @default.
• W2023407910 crossrefType "journal-article" @default.
• W2023407910 hasAuthorship W2023407910A5013792017 @default.
• W2023407910 hasAuthorship W2023407910A5046319428 @default.
• W2023407910 hasAuthorship W2023407910A5057207847 @default.
• W2023407910 hasAuthorship W2023407910A5061157288 @default.
• W2023407910 hasAuthorship W2023407910A5065493500 @default.
• W2023407910 hasAuthorship W2023407910A5079489429 @default.
• W2023407910 hasAuthorship W2023407910A5080693514 @default.
• W2023407910 hasAuthorship W2023407910A5087905831 @default.
• W2023407910 hasBestOaLocation W20234079101 @default.
• W2023407910 hasConcept C121608353 @default.
• W2023407910 hasConcept C126322002 @default.
• W2023407910 hasConcept C143998085 @default.
• W2023407910 hasConcept C2776364478 @default.
• W2023407910 hasConcept C2777478702 @default.
• W2023407910 hasConcept C2778260052 @default.
• W2023407910 hasConcept C2778367456 @default.
• W2023407910 hasConcept C2780456651 @default.
• W2023407910 hasConcept C2780962732 @default.
• W2023407910 hasConcept C2781413609 @default.
• W2023407910 hasConcept C526805850 @default.
• W2023407910 hasConcept C71924100 @default.
• W2023407910 hasConcept C90924648 @default.
• W2023407910 hasConcept C98274493 @default.
• W2023407910 hasConceptScore W2023407910C121608353 @default.
• W2023407910 hasConceptScore W2023407910C126322002 @default.
• W2023407910 hasConceptScore W2023407910C143998085 @default.
• W2023407910 hasConceptScore W2023407910C2776364478 @default.
• W2023407910 hasConceptScore W2023407910C2777478702 @default.
• W2023407910 hasConceptScore W2023407910C2778260052 @default.
• W2023407910 hasConceptScore W2023407910C2778367456 @default.
• W2023407910 hasConceptScore W2023407910C2780456651 @default.
• W2023407910 hasConceptScore W2023407910C2780962732 @default.
• W2023407910 hasConceptScore W2023407910C2781413609 @default.

• next